Business
CollPlant Announces Publication of Study in Science Translational Medicine Showing Composite Matrix Based on rhCollagen, Ceramics and Bone Morphogenic Protein Led to Bone Growth Superior to Standard of Care
REHOVOT, Israel, April 24, 2019 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative medicine company, today announced the publication of a study titled,
About this update from Collplant Biotechnologies Ltd.
[{"type":"text","content":" REHOVOT, Israel, April 24, 2019 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative medicine company, today announced the publication of a study titled, \"Bone Repair with a Receptor Optimized BMP-2/6/Activin Chimera Delivered In a Novel Ceramic/rhCollagen Matrix is Superior to BMP-2\" in the April issue of Science Translational Medicine. The study was led by Bioventus which developed the Matrix with CollPlant. \nHuman bone morphogenetic proteins (BMP)s are FDA approved for use in humans as bone graft substitutes and are typically delivered through an absorbable collagen sponge (ACS). However, in order to be efficacious, BMPs are delivered in high doses which can lead to serious side effects including an increased risk of uncontrolled bone formation and cancer.\nThe published article reports results from a study in non-human primates for bone regeneration using a receptor optimized chimera version of BMP-2/BMP-6/activin A delivered in a composite matrix formulated with CollPlant's rhCollagen and ceramic granules. The rhCollagen matrix was specifically designed for high retention of the BMP chimera and has a unique design for cell infiltration and bone tissue growth. The treatment demonstrated tissue ingrowth that generated superior bone formation at concentrations of BMP that were 1/10th to 1/30th of the standard dosage of BMP-2 concentration approved by the FDA for clinical use in humans. \n\"We are very pleased with the excellent results of this collaborative study. Our rhCollagen served as a very effective delivery vehicle for the BMP version used in this study. The study results demonstrate the potential for a new treatment that is far superior to the current standard of care in terms of both efficacy and safety. Moreover, the far improved safety profile resulting from a significant dose reduction of the BMP used in standard of care may expand the opportunities for using this treatment in a broader range of patients,\" stated Yehiel Tal, CollPlant's Chief Executive Officer. \n\"We believe our rhCollagen is the ideal building block for scaffolds used in regenerative medicine applications, including orthobiologics in both hard and soft tissue repair, 3D bioprinting of tissues and organs, medical aesthetics, and advanced wound care,\" concluded Mr. Tal.\nAbout CollPlantCollPlant is a regenerative medicine company focused ...